Actions d’un progestatif dérivé de la 19-norprogestérone sur la glande mammaire : le nomégestrol acétate

Schindler, 1998, Aspects of progestin activity on the breast, Maturitas, 29, 61, 10.1016/S0378-5122(98)00029-2 Sitruk-Ware, 2003, Progestins in hormonal replacement therapy (HRT) : new molecules, risks and benefits, Ann Endocrinol, 64, 178 Rossouw, 2002, Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial, J Am Med Assoc, 288, 321, 10.1001/jama.288.3.321 Beral, 2003, Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet, 362, 419, 10.1016/S0140-6736(03)14596-5 1997, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer, Lancet, 350, 1047, 10.1016/S0140-6736(97)08233-0 Anderson, 2004, Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial, J Am Med Assoc, 291, 1701, 10.1001/jama.291.14.1701 Duc, 1990, Nomegestrol acetate binding to cytosolic progesterone receptor in human mammary gland, Med Sci Res, 18, 57 Duc, 1991, Liaison de l’acétate de nomégestrol aux récepteurs de la progestérone de l’endomètre et du tissu mammaire humain, Contracept Fertil Sex, 19, 995 Botella, 1994, Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells, J Steroid Biochem Mol Biol, 50, 41, 10.1016/0960-0760(94)90170-8 Graham, 1995, Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells, J Biol Chem, 270, 30693, 10.1074/jbc.270.51.30693 Pasqualini, 2001, Biological effects of progestins in breast cancer, Gynecol Endocrinol, 15, 44, 10.1080/gye.15.s6.44.52 Alexander, 1990, Progestin regulation of estrogen receptor messenger RNA in human breast cancer cells, Mol Endocrinol, 4, 821, 10.1210/mend-4-6-821 Catherino, 1995, Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity, J Steroid Biochem Mol Biol, 55, 239, 10.1016/0960-0760(95)00171-U Botella, 1995, Lack of estrogenic potential of progesterone or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosterone derivatives on endometrial Ishikawa cells, J Steroid Biochem Mol Biol, 55, 77, 10.1016/0960-0760(95)00156-T Shields-Botella, 2003, An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells, J Steroid Biochem Mol Biol, 87, 111, 10.1016/j.jsbmb.2003.08.003 Jeng, 1992, Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation, Cancer Res, 52, 6539 Jordan, 1993, The estrogenic activity of synthetic progestins used in oral contraceptives, Cancer, 71, 1501, 10.1002/cncr.2820710415 Botella, 1989, Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative, J Pharmacol Exp Ther, 248, 758 Rabe, 2000, Induction of estrogen receptor-α and –β activities by synthetic progestins, Gynecol Endocrinol, 14, 118, 10.3109/09513590009167670 Botella, 1987, The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor-progestagen, on the rat prostate, Acta Endocrinologica, 115, 544, 10.1530/acta.0.1150544 Duc, 1995, Antiandrogenic properties of nomegestrol acetate, Arzneim Forsch/Drug Res, 45, 70 Basdevant, 1991, Effects of nomesgestrol acetate (5mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women, Contraception, 44, 599, 10.1016/0010-7824(91)90080-Y Sasano, 1998, Intratumoral aromatase in human breast, endometrial, and ovarian malignancies, Endocr Rev, 19, 593, 10.1210/er.19.5.593 Suzuki, 2002, In situ production of estrogens in human breast carcinoma, Breast Cancer, 9, 296, 10.1007/BF02967607 Clemons, 2001, Estrogen and the risk of breast cancer, N Engl J Med, 344, 276, 10.1056/NEJM200101253440407 Chetrite, 2000, Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues, J Steroid Biochem Mol Biol, 72, 23, 10.1016/S0960-0760(00)00040-6 Pasqualini, 1996, Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients, J Clin Endocrinol Metab, 81, 1460, 10.1210/jc.81.4.1460 Vermeulen, 1986, Steroid dynamics in the normal and carcinomatous mammary gland, J Steroid Biochem, 25, 799, 10.1016/0022-4731(86)90311-0 Santner, 1984, In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway, J Clin Endocrinol Metab, 59, 29, 10.1210/jcem-59-1-29 Chetrite, 2001, The selective estrogen enzyme modulator (SEEM) in breast cancer, J Steroid Biochem Mol Biol, 76, 95, 10.1016/S0960-0760(01)00046-2 Reed, 1989, In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione, Int J Cancer, 44, 233, 10.1002/ijc.2910440208 Miyoshi, 2001, Involvement of up-regulation of 17β-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers, Int J Cancer, 94, 685, 10.1002/ijc.1525 Pasqualini, 1999, Biological effects of progestins in breast cancer, Gynecol Endocrinol, 13, 11, 10.1080/gye.13.s4.11.19 Pasqualini, 1999, Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications, J Steroid Biochem Mol Biol, 69, 287, 10.1016/S0960-0760(99)00082-5 Labrie, 2000, Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease, J Mol Endocrinol, 25, 1, 10.1677/jme.0.0250001 Pasqualini, 1998, Progestins and breast cancer, J Steroid Biochem Mol Biol, 65, 225, 10.1016/S0960-0760(98)00028-4 Chetrite, 1996, Effect of nomegestrol acetate on estrone-sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells, J Steroid Biochem Mol Biol, 58, 525, 10.1016/0960-0760(96)00094-5 Chetrite, 2003, Effect of nomegestrol acetate on human estrogen sufotransferase activity in the hormone-dependent MCF-7 and T-47D breast cancer cell lines, Anticancer Res, 23, 4651 Anderson, 1982, Cell turnover in the “resting” human breast : influence of parity, contraceptive pill, age and laterality, Br J Cancer, 46, 376, 10.1038/bjc.1982.213 Ferguson, 1981, Morphological evaluation of cell turnover in relation to the menstrual cycle in the “resting” human breast, Br J Cancer, 44, 177, 10.1038/bjc.1981.168 Seeger, 2003, The effect of progesterone and synthetic progestins on serum and estradiol-stimulated proliferation of human breast cancer cells, Horm Metab Res, 35, 76, 10.1055/s-2003-39061 De Lignières, 2002, Effects of progestogens on the postmenopausal breast, Climacteric, 5, 229, 10.1080/cmt.5.3.229.235 Gompel, 2000, Hormonal regulation of apoptosis in breast cells and tissues, Steroids, 65, 593, 10.1016/S0039-128X(00)00172-0 Desreux, 1998, Effets des progestatifs sur l’apoptose des cellules épithéliales mammaires, in vivo et in vitro, Reprod Hum Horm, 11, 273 Desreux, 2000, Progesterone receptor activation, an alternative to SERMs in breast cancer, Eur J Cancer, 36, S90, 10.1016/S0959-8049(00)00243-4 Desreux, 2003, Effects of a progestogen on normal human breast epithelial cell apoptosis in vitro and in vivo, Breast, 12, 142, 10.1016/S0960-9776(03)00003-1 Van Den Brûle, 2001, Influence du régime d’administration continu ou discontinu d’acétate de nomégestrol sur l’apoptose des cellules mammaires, Reprod Hum Horm, 14, 243 Li, 2001, Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line, Breast Cancer Res, 3, 253, 10.1186/bcr303 Jamin, 2003, Antigonadotropic effects of a 19-nor-progesterone derivative: the example of nomegestrol acetate, Gynecol Obstet Fertil, 31, 70, 10.1016/S1297-9589(02)00009-7 Colin, 1978, Relationship of mastodynia with its endocrine environment and treatment in a double blind trial with lynestrenol, Arch Gynakol, 225, 7, 10.1007/BF00672829 Kubista, 1987, Treatment of mastopathies with cyclic mastodynia. Clinical results and hormonal profiles, Rev Fr Gynecol Obstet, 82, 221 Maddox, 1990, A randomised controlled trial of medroxyprogesterone acetate in mastalgia, Ann R Coll Surg Engl, 72, 71 Nappi, 1992, Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease, J Endocrinol Invest, 15, 801, 10.1007/BF03348808 Uzan, 1992, Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease, Eur J Obstet Gynecol Reprod Biol, 43, 219, 10.1016/0028-2243(92)90177-Z Pons, 1996, L’acétate de nomégestrol dans le traitement des mastopathies bénignes résultats d’un essai contrôlé, J Le Sein, 6, 3 Winkler, 2001, Cyclic progestin therapy for the management of mastopathy and mastodynia, Gynecol Endocrinol, 15, 37, 10.1080/gye.15.s6.37.43 Plu-Bureau, 1992, Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among french women, Br J Cancer, 65, 945, 10.1038/bjc.1992.198 Plu-Bureau, 1994, Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease, Br J Cancer, 70, 270, 10.1038/bjc.1994.291 Barton, 1999, The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How?, J Am Med Assoc, 282, 1270, 10.1001/jama.282.13.1270 Mandelson, 2000, Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers, J Natl Cancer Inst, 92, 1081, 10.1093/jnci/92.13.1081 Colau, 1996, Impact du nomégestrol acétate sur la qualité de vie chez la femme ménopausée : une étude multicentrique randomisée, 119 Foidart, 1997, Impact of percutaneous oestradiol gels in postmenopausal hormone replacement therapy on clinical symptoms and endometrium, Br J Obstet Gynaecol, 104, 305, 10.1111/j.1471-0528.1997.tb11458.x Lesur, 2002, Pour en finir avec la densité mammaire et le traitement hormonal substitutif de la ménopause, Reprod Hum Horm, 15, 341 Lesur-Schwander, 2003, Le sein à la menopause : traitement hormonal substitutif classique ou alternatives ? Le point de vue du sénologue, Rev Prat Gynecol Obstet, 72, 34 Colacurci, 1998, Effects of tibolone on the breast, Eur J Obstet Gynecol Reprod Biol, 80, 235, 10.1016/S0301-2115(98)00129-8 Colacurci, 2001, Effects of a short-term suspension of hormone replacement therapy on mammographic density, Fertil Steril, 76, 451, 10.1016/S0015-0282(01)01967-7 Colacurci, 2001, Effects of different types of hormone replacement therapy on mammographic density, Maturitas, 40, 159, 10.1016/S0378-5122(01)00232-8 Greendale, 1999, Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators, Ann Intern Med, 130, 262, 10.7326/0003-4819-130-4_Part_1-199902160-00003